Anti-angiogenesis in neuroblastoma

Critical Reviews in Oncology/Hematology

Volumn 86, Issue 3, 2013, Pages 212-221

  Ribatti, Domenico ^a  

^a UNIVERSITY OF BARI   (Italy)

Author keywords

Angiogenesis; Anti angiogenesis; Neuroblastoma; Tumour growth

Indexed keywords

4 [4 (4' CHLORO 2 BIPHENYLYLMETHYL) 1 PIPERAZINYL] N [4 [3 DIMETHYLAMINO 1 (PHENYLTHIOMETHYL)PROPYLAMINO] 3 NITROBENZENESULFONYL]BENZAMIDE; ALPHA INTERFERON; ANGIOGENESIS INHIBITOR; ARGATROBAN; BETA INTERFERON; BEVACIZUMAB; BORTEZOMIB; CEDIRANIB; CYCLOPHOSPHAMIDE; DOXORUBICIN; ENDOSTATIN; FENRETINIDE; FUMAGILLOL CHLOROACETYLCARBAMATE; IMATINIB; MONOCLONAL ANTIBODY DC101; N ACETYLSARCOSYLGLYCYLVALYL DEXTRO ALLOISOLEUCYLTHREONYLNORVALYLISOLEUCYLARGINYLPROLINE ETHYLAMIDE; NUTLIN 3; PROTEIN TYROSINE KINASE INHIBITOR; RAPAMYCIN; SEMAXANIB; SU 11657; SUNITINIB; TRICHOSTATIN A; UNCLASSIFIED DRUG; VALPROIC ACID; VASCULAR TARGETING AGENT; VASCULOTROPIN INHIBITOR; VINBLASTINE;

ANTIANGIOGENIC ACTIVITY; COMBINATION CHEMOTHERAPY; CONTINUOUS INFUSION; DOSAGE SCHEDULE COMPARISON; DOSE RESPONSE; DRUG EFFICACY; DRUG INTERMITTENT THERAPY; DRUG MECHANISM; DRUG POTENTIATION; DRUG RESPONSE; DRUG TARGETING; GENE THERAPY; HUMAN; IMMUNOTHERAPY; LOW DRUG DOSE; MONOTHERAPY; NEUROBLASTOMA; NONHUMAN; PHAGE DISPLAY; REVIEW; TUMOR VASCULARIZATION;

ANGIOGENESIS INHIBITORS; ANTINEOPLASTIC AGENTS; ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; GENETIC THERAPY; HUMANS; IMMUNOTHERAPY; MOLECULAR TARGETED THERAPY; NEOVASCULARIZATION, PATHOLOGIC; NEUROBLASTOMA;

EID: 84877829244     PISSN: 10408428     EISSN: 18790461     Source Type: Journal    
DOI: 10.1016/j.critrevonc.2012.11.004     Document Type: Review

References (76)

1. Ribatti D., Nico B., Crivellato E., Roccaro A.M., Vacca A. The history of the angiogenic switch concept. Leukemia 2007, 21:44-52.
2. Eggert A., Ikegaki N., Kwiatkowski J., Zhao H., Brodeur G.M., Himelstein B.P. High-level expression of angiogenic factors is associated with advanced tumor stage in human neuroblastoma. Clinical Cancer Research 2000, 6:1900-1908.
3. Ribatti D., Alessandri G., Vacca A., Iurlaro M., Ponzoni M. Human neuroblastoma cells produce extracellular matrix-degrading enzymes, induce endothelial cell proliferation and are angiogenic in vivo. International Journal of Cancer 1998, 77:449-454.
4. Ribatti D., Poliani P.L., Longo V., Mangieri D., Nico B., Vacca A. Erythropoietin/erythropoietin receptor system is involved in angiogenesis in human neuroblastoma. Histopathology 2007, 50:636-641.
5. Katzenstein H.M., Rademaker A.W., Senger C., et al. Effectiveness of the angiogenesis inhibitor TNP-470 in reducing the growth of human neuroblastoma in nude mice inversely correlates with the tumor burden. Clinical Cancer Research 1999, 5:4273-4278.
6. Ribatti D., Surico G., Vacca A., et al. Angiogenesis extent and expression of matrix metalloproteinase-2 and -9 correlate with progression in human neuroblastoma. Life Sciences 2001, 68:1161-1168.
7. Ribatti D., Raffaghello L., Pastorino F., et al. In vivo angiogenic activity of neuroblastoma correlates with MYCN oncogene overexpression. International Journal of Cancer 2002, 102:351-354.
8. Ribatti D., Marimpietri D., Pastorino F., et al. Angiogenesis in neuroblastoma. Annals of the New York Academy of Sciences 2004, 1028:133-142.
9. Das B., Yeger H., Tsuchida R., et al. A hypoxia-driven vascular endothelial growth factor/Flt1 autocrine loop-interacts with hypoxia-inducible factor-1α through mitogenic-activated protein kinase/extracellular signal-regulated kinase 1/2 pathway in neuroblastoma. Cancer Research 2005, 65:7267-7275.
10. Huang D., Rutkowski J.L., Brodeur G.M., et al. Schwann cell-conditioned medium inhibits angiogenesis. Cancer Research 2000, 60:5966-5971.
11. Chlenski A., Liu S., Crawford S.E., et al. SPARC is a key Schwannian-derived inhibitor controlling neuroblastoma tumor angiogenesis. Cancer Research 2002, 62:7357-7363.
12. Crawford S.E., Stellmach V., Ranalli M., et al. Pigment epithelium-derived factor (PEDF) in neuroblastoma: a multifunctional mediator of Schwann cell antitumor activity. Journal of Cell Science 2001, 114:4421-4428.
13. Liu S., Tian Y., Chlenski A., et al. Cross-talk between Schwann cells and neuroblasts influences the biology of neuroblastoma xenografts. American Journal of Pathology 2005, 166:891-900.
14. Zeine R., Salwen H.R., Peddinti R., et al. Presence of cancer-associated fibroblasts inversely correlates with Schwannian stroma in neuroblastoma tumors. Modern Pathology 2009, 22:950-958.
15. Eggert A., Grotzer M.A., Ikegaki N., Liu X.G., Evans A.E., Brodeur G.M. Expression of the neurotrophin receptor TrkA down-regulates expression and function of angiogenic stimulators in SH-SY5Y neuroblastoma cells. Cancer Research 2002, 62:1802-1808.
16. Folkman J. Tumor angiogenesis: therapeutic implications. New England Journal of Medicine 1971, 285:1182-1186.
17. Ribatti D., Ponzoni M. Antiangiogenic strategies in neuroblastoma. Cancer Treatment Reviews 2005, 31:27-34.
18. Ribatti D., Alessandri G., Baronio M., et al. Inhibition of neuroblastoma-induced angiogenesis by fenretinide. International Journal of Cancer 2001, 94:314-321.
19. Castle V.P., Ou X., O'Shea S., Dixit V.M. Induction of thrombospondin 1 by retinoic acid is important during differentiation of neuroblastoma cells. Journal of Clinical Investigation 1992, 90:1857-1863.
20. Wassberg E., Pahlman S., Westlin J.E., Christofferson R. The angiogenesis inhibitor TNP-470 reduces the growth rate of human neuroblastoma in nude rats. Pediatric Research 1997, 41:327-333.
21. Nagabuchi E., Vanderkolk W.E., Une Y., Ziegler M.M. TNP-470 antiangiogenic therapy for advanced murine neuroblastoma. Journal of Pediatric Surgery 1997, 32:287-293.
22. Katzenstein H.M., Cohn S.L., Crawford S., Meitar D. Angiogenesis in neuroblastoma. Journal of Clinical Oncology 2000, 18:2789-2791.
23. Wassberg E., Hedborg F., Skoldenberge E., Stridsberg R., Christofferson E. Inhibition of angiogenesis induced chromaffin differentiation and apoptosis in neuroblastoma. American Journal of Pathology 1999, 154:395-400.
24. Shusterman S., Grupp S.A., Maris J.M. Inhibition of tumor growth in a human neuroblastoma xenograft model with TNP-470. Medical and Pediatric Oncology 2010, 35:673-676.
25. Shusterman S., Grupp S.A., Barr R., Carpentieri D., Zhao H., Maris J.M. The angiogenesis inhibitor TNP-470 effectively inhibits human neuroblastoma xenografts growth, especially in the setting of subclinical disease. Clinical Cancer Research 2001, 7:977-984.
26. Kaicker S., McCrudden K.M., Beck L., et al. Thalidomide is anti-angiogenic in a xenograft model of neuroblastoma. International Journal of Oncology 2003, 23:1651-1655.
27. Davidoff A.M., Leary M.A., Ng C.Y., et al. Autocrine expression of both endostatin and green fluorescent protein provides a synergistic antitumor effect in a murine neuroblastoma model. Cancer Gene Therapy 2001, 8:537-545.
28. Kuroiwa M., Takeuchi T., Lee J.H., et al. Continuous versus intermittent administration of human endostatin in xenografted human neuroblastoma. Journal of Pediatric Surgery 2003, 38:1499-1505.
29. Streck C., Zhang Y., Zhou J., Ng C.Y.G., Davidoff A. Endostatin-mediated concomitant resistance in neuroblastoma. Journal of Pediatric Surgery 2004, 39:405-411.
30. Brignole C., Marimpietri D., Pastorino F., et al. Effects of bortezomib on human neuroblastoma cell growth, apoptosis, and angiogenesis. Journal of the National Cancer Institute 2006, 98:1142-1157.
31. Sarker K.P., Biswas K.K., Yamaji K., et al. Inhibition of thrombin-induced vascular endothelial growth factor production in human neuroblastoma (NB-1) cells by aragtroban. Pathophysiology of Hemostasis and Thrombosis 2005, 34:41-47.
32. Marimpietri D., Nico B., Vacca A., et al. Synergistic inhibition of human neuroblastoma-related angiogenesis by vinblastine and rapamycin. Oncogene 2005, 24:6785-6795.
33. Marimpietri D., Brignole C., Nico B., et al. Combined therapeutic effects of vinblastine and rapamycin on human neuroblastoma growth, apoptosis, and angiogenesis. Clinical Cancer Research 2007, 13:3977-3988.
34. Pagnan G., Di Paolo D., Carosio R., et al. The combined therapeutic effects of bortezomib and fenretinide on neuroblastoma cells involve endoplasmic reticulum stress response. Clinical Cancer Research 2009, 15:1199-1209.
35. Fang H., Harned T.M., Kalous O., Maldonado V., De Clerck Y.A., Reynolds C.P. Synergistic activity of fenretinide and the Bcl-2 family protein inhibitor ABT-737 against human neuroblastoma. Clinical Cancer Research 2011, 17:7093-7104.
36. Zhang L., Smith K.M., Chong A.L., et al. In vivo antitumor and antimetastatic activity of sunitinib in preclinical neuroblastoma mouse model. Neoplasia 2009, 11:426-435.
37. Yang Q., Tian Y., Liu S., et al. Thrombospondin-1 peptide ABT-510 combined with valproic acid is an effective antiangiogenesis strategy in neuroblastoma. Cancer Research 2007, 67:1716-1724.
38. Gong H., Pottgen C., Stuben G., Havers W., Stuschke M., Schweigerer L. Arginine deiminase and other antiangiogenic agents inhibit unfavorable neuroblastoma growth: potentiation by irradiation. International Journal of Cancer 2003, 106:723-728.
39. Kuljaca S., Liu T., Tee E.A., et al. Enhancing the anti-angiogenic action of histone deacetylase inhibitors. Molecular Cancer 2007, 6:68.
40. Cinatl J., Kotchetkov R., Blaheta R., Driever P.H., Vogel J.U., Cinatl J. Induction of differentiation and suppression of malignant phenotype of human neuroblastoma BE(2)-C cells by valproic acid: enhancement by combination with interferon alpha. International Journal of Oncology 2002, 20:97-106.
41. Kim E., Moore J., Huang J., et al. All angiogenesis is not the same: distinct patterns of response to antiangiogenic therapy in experimental neuroblastoma and Wilms tumor. Journal of Pediatric Surgery 2001, 36:287-290.
42. Kim E.S., Soffer S.Z., Huang J., et al. Distinct response of experimental neuroblastoma to combination antiangiogenic strategies. Journal of Pediatric Surgery 2002, 37:518-522.
43. Kim E.S., Seru A., Huang J., Potent VEGF, et al. blockade causes regression of coopted vessels in a model of neuroblastoma. Proceedings of the National Academy of Sciences of the United States of America 2002, 99:11399-11404.
44. Segerström L., Fuchs D., Bäckman U., Holmquist K., Christofferson R., Azarbayjani F. The anti-VEGF antibody bevacizumab potently reduces the growth rate of high-risk neuroblastoma xenografts. Pediatric Research 2006, 60:576-581.
45. Dickson P.V., Hamner J.B., Sims T.L., et al. Bevacizumab-induced transient remodeling of the vasculature in neuroblastoma xenografts results in improved delivery and efficacy of systemically administered chemotherapy. Clinical Cancer Research 2007, 13:3942-3950.
46. Patterson D.M., Gao D., Trahan D.N., et al. Effect of MDM2 and vascular endothelial growth factor inhibition on tumor angiogenesis and metastasis in neuroblastoma. Angiogenesis 2011, 14:255-266.
47. Barbieri E., Metha P., Chen Z., et al. MDH2 inhibition sensitizes neuroblastoma to chemotherapy-induced apoptotic cell death. Molecular Cancer Therapeutics 2006, 5:2358-2365.
48. Klement G., Baruchel S., Rak J., et al. Continuous low-dose therapy with vinblastine and VEGF receptor-2 antibody induces sustained tumor regression without overt toxicity. Journal of Clinical Investigation 2000, 105:1049-1058.
49. Bäckman U., Svensson A., Christofferson R. Importance of vascular endothelial growth factor A in the progression of experimental neuroblastoma. Angiogenesis 2002, 5:267-274.
50. Maris J.M., Courtright J., Houghton P.J., et al. Initial testing of the VEGFR inhibitor AZD2171 by the Pediatric Preclinical testing Program. Pediatric Blood & Cancer 2008, 50:581-587.
51. Gomes E., Rockwell P. P38 MAPK as a negative regulator of VEGF/VEGFR2 signaling pathway in serum deprived human SK-N-SH neuroblastoma cells. Neuroscience Letters 2008, 431:95-100.
52. Bäckman U., Christofferson R. The selective calls III/IV receptor tyrosine kinase inhibitor SU11657 inhibits tumor growth and angiogenesis in experimental neuroblastoma grown in mice. Pediatric Research 2000, 57:690-695.
53. Beppu K., Jaboine J., Merchant M.S., Mackall C.L., Thiele C.J. Effect of imatinib mesylate on neuroblastoma tumorigenesis and vascular endothelial growth factor expression. Journal of the National Cancer Institute 2004, 96:46-55.
54. Streck C., Dickson P.V., Ng C.Y., et al. Adeno-associated virus vector-mediated systemic delivery of IFN-β combined with low-dose cyclophosphamide affects tumor regression in murine neuroblastoma models. Clinical Cancer Research 2005, 11:6020-6029.
55. Lode H.N., Moehler T., Xiang R., et al. Synergy between an antiangiogenic integrin αv antagonist and an antibody-cytokine fusion protein eradicates spontaneous tumor metastasis. Proceedings of the National Academy of Sciences of the United States of America 1999, 96:1591-1596.
56. Pastorino F., Brignole C., Marimpietri D., et al. Vascular damage and anti-angiogenic effects of tumor vessel-targeted liposomal chemotherapy. Cancer Research 2003, 63:7400-7409.
57. Pastorino F., Brignole C., Di Paolo D., et al. Targeting liposomal chemotherapy via both tumor cell-specific and tumor vasculature-specific ligands potentiates therapeutic efficacy. Cancer Research 2006, 66:10073-10082.
58. Pastorino F., Di Paolo D., Piccardi F., et al. Enhanced antitumor efficacy of clinical-grade vasculature-targeted liposomal doxorubicin. Clinical Cancer Research 2008, 14:7320-7329.
59. Pasqualini R., Koivunen E., Kain R., Aminopeptidase N, et al. is a receptor for tumor-homing peptides and a target for inhibiting angiogenesis. Cancer Research 2000, 60:722-727.
60. Marchiò S., Lahdenranta J., Schlingemann R.O., Aminopeptidase A, et al. is a functional target in angiogenic blood vessels. Cancer Cell 2004, 5:151-162.
61. Schlingemann R.O., Oosterwijk E., Wesseling P., Rietveld F.J., Ruiter D.J. Aminopeptidase is a constituent of activated pericytes in angiogenesis. Journal of Pathology 1996, 179:436-442.
62. Loi M., Marchiò S., Becherini P., et al. Combined targeting of perivascular and endothelial tumor cells enhances anti-tumor efficacy of liposomal chemotherapy in neuroblastoma. Journal of Controlled Release 2010, 145:66-73.
63. Ribatti D. The history of angiogenesis inhibitors. Leukemia 2007, 21:1606-1609.
64. Hida K., Hida Y., Amin D.N., et al. Tumor-associated endothelial cells with cytogenic abnormalities. Cancer Research 2004, 64:8249-8255.
65. Ribatti D. Antiangiogenic therapy accelerates tumor metastasis. Leukemia Research 2011, 35:24-26.
66. Grothey A., Sugrue M.M., Purdie D.M., et al. Bevacizumab beyond first progression is associated with prolonged overall survival in metastatic colorectal cancer: results from a large observational cohort study (BriTE). Journal of Clinical Oncology 2008, 26:5326-5344.
67. Casanovas O., Hicklin D.J., Bergers G., Hanahan D. Drug resistance by evasion of antiangiogenic targeting of VEGF signaling in late-stage pancreatic islet tumors. Cancer Cell 2005, 8:299-309.
68. Seftor R.E.B., Hess A.R., Seftor E.A., et al. Tumor cell vasculogenic mimicry. From controversy to therapeutic promise. American Journal of Pathology 2012, 181:1115-1125.
69. Pezzolo A., Parodi F., Corrias M.V., Cinti R., Gambini C., Pistoia V. Tumor origin of endothelial cells in human neuroblastoma. Journal of Clinical Oncology 2007, 25:376-383.
70. Ribatti D., Nico B., Pezzolo A., et al. Angiogenesis in a human neuroblastoma xenograft model: mechanisms and inhibition by tumor-derived interferon-gamma. British Journal of Cancer 2006, 94:1845-1852.
71. Maris J.M., Hogarthy M.D., Bagattel R., Cohn S.L. Neuroblastoma. The Lancet 2007, 369:2106-2120.
72. Matthay K.K., Villablanca J.G., Seeger R.C., et al. Children's Cancer Group. Treatment of high-risk neuroblastoma with intensive chemotherapy, radiotherapy, autologous bone marrow transplantation, and 13-cis-retinoic acid. New England Journal of Medicine 1999, 341:1165-1173.
73. Michaelis M., Hinsch N., Michaelis U.R., et al. Chemotherapy-associated angiogenesis in neuroblastoma tumors. American Journal of Pathology 2012, 180:1370-1377.
74. Shaked Y., Ciarrocchi A., Franco M., et al. Therapy-induced acute recruitment of circulating endothelial progenitor cells to tumors. Science 2006, 313:1785-1787.
75. Glade Bender J.L., Adamsons P.C., Reid J.M., et al. Phase I trial and pharmacokinetic study of bevacizumab in pediatric patients with refractory solid tumors: a Children's Oncology Group Study. Journal of Clinical Oncology 2008, 26:399-405.
76. Benesch M., Windelberg M., Sauseng W., et al. Compassionate use of bevacizumab (Avastin) in children and young adults with refractory or recurrent solid tumors. Annals of Oncology 2008, 19:807-813.